Erkki Ruoslahti,
Distinguished Professor and Former President,
Sanford Burnham Prebys Medical Discovery Institute
Dr. Erkki Ruoslahti is Distinguished Professor and former president of Sanford-Burnham Institute for Medical Research and a founder of the Center for Nanomedicine at University of California, Santa Barbara. Dr. Ruoslahti is a pioneer in the field of cell adhesion. His main discovery and invention is the integrin-binding tripeptide motif RGD and integrins that recognize this motif. He now studies specific vascular addresses in directing drugs to sites of disease. Dr. Ruoslahti’s is a member of the U.S. National Academy of Sciences and National Academy of Medicine. He is the recipient of a number of awards, including the Japan Prize and Gairdner Award, and Knight and Commander of the Orders of White Rose of Finland and Lion of Finland.
Disease-Specific Vascular Markers for Cancer, Atherosclerosis and Brain Diseases
Wednesday, 27 March 2019 at 09:30
Add to Calendar ▼2019-03-27 00:00:002019-03-27 01:00:00Europe/LondonDisease-Specific Vascular Markers for Cancer, Atherosclerosis and Brain DiseasesLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
We study peptides that home to specific targets in the body. We discover
the homing peptides by screening phage libraries for peptides that
direct homing of phages to the target tissue in vivo. The homing
peptides, which usually bind to receptors in the vessels of the target
tissue, can be used to selectively deliver diagnostic probes and drugs
to the target. The latest development is the discovery of
tumor-penetrating peptides. These peptides activate an endocytic bulk
transport pathway we have dubbed the CendR pathway, which can enhance
the exit from blood and tissue penetration co-administered compounds
even without chemical coupling to the peptide (Ruoslahti, Adv Mater.
(2012) 24 3747). We have also identified peptides specific for
atherosclerotic plaques, accumulate at the site of a brain injury or
recognize the blood vessels in Alzheimer’s disease brain. Our homing
frequency have an intrinsic biological active I the disease they target.
Examples of the peptide discovery process from initial screening to
clinical trials will be given.
Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-03-27 00:00:002019-03-27 01:00:00Europe/LondonDisease-Specific Vascular Markers for Cancer, Atherosclerosis and Brain DiseasesLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
